ORDER

New Delhi, the 9th May, 2022

S.O. 2165(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

TABLE

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s Optimus Pharma Pvt. Ltd. / M/s Natco Pharma Ltd.	8.04
2.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s MSN Laboratories Private Limited / M/s Emcure Pharmaceuticals Limited	14.65
3.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s MSN Laboratories Private Limited / M/s Eris Lifesciences Limited	14.65
4.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s Micro Labs Limited	10.63
5.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s Optimus Pharma Pvt. Ltd. / M/s Natco Pharma Ltd.	8.37
6.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s MSN Laboratories Private Limited / M/s Emcure Pharmaceuticals Limited	16.33
7.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s Micro labs Limited	11.52
8.	Linagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Linagliptin 2.5mg Metformin Hydrochloride IP 850mg	1 Tablet	M/s MSN Laboratories Private Limited / M/s Emcure Pharmaceuticals Limited	15.45

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
9.	Sitagliptin Phosphate + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP 64.25mg is eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Limited	20.02
10.	Sitagliptin Phosphate + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP 64.25mg is eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Limited	18.34
11.	Sitagliptin Phosphate + Metformin Hydrochloride(Extended release) Tablet	**Each film coated bilayered tablet contains:** Sitagliptin Phosphate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (As an Extended release form)	1 Tablet	M/s Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Limited	20.17
12.	Sitagliptin Phosphate + Metformin Hydrochloride (Extended release) Tablet	**Each film coated bilayered tablet contains:** Sitagliptin Phosphate eq. to Sitagliptin 100mg Metformin Hydrochloride IP 1000mg (As an Extended release form)	1 Tablet	M/s Alkem Healthsciences (A Unit of Alkem Laboratories Ltd.) / M/s Alkem Laboratories Limited	19.81
13.	Sitagliptin Phosphate + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited	18.34
14.	Sitagliptin Phosphate + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited	20.02
15.	Sitagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s Zydus Healthcare Limited	18.34
16.	Sitagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s Zydus Healthcare Limited	20.02

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
17.	Sitagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 500mg	1 Tablet	M/s Morepen Laboratories Limited	18.34
18.	Sitagliptin + Metformin Hydrochloride Tablet	**Each film coated tablet contains:** Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 50mg Metformin Hydrochloride IP 1000mg	1 Tablet	M/s Morepen Laboratories Limited	20.02

Note:

(a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

[PN/229/97/2022/F/F. No. 8(97)/2022/D.P./NPPA-Div.-II]

PRASENJIT DAS, Dy. Director

आदेश

नई दिल्ली, 9 मई, 2022

का.आ. 2166(अ).—औषध विभाग द्वारा नीचे दी गई सारणी के स्तंभ (6) में विनिर्दिष्ट पुनर्विलोकन आदेश और पत्रों के द्वारा दिये गए निर्देशों के कार्यान्वयन में और भारत सरकार के रसायन और उर्वरक मंत्रालय द्वारा जारी का.आ. 1394(अ) तारीख 30 मई, 2013 और का.आ. 701(अ) तारीख 10 मार्च, 2016 के साथ पठित औषध (कीमत नियंत्रण) आदेश, 2013 के पैरा 5 11 और 15 द्वारा प्रदत्त शक्तियों का प्रयोग करते हुए, सारणी के स्तंभ (7) में विनिर्दिष्ट भारत सरकार के रसायन और